SAN CARLOS, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of ...
Note: Articles may be assigned to more than one subject area, as a result the sum of the subject research outputs may not equal the overall research outputs. Actionable insights into research ...
Biomolecular phase separation-mediated immunity was recently uncovered as an important strategy of plants and animals for their survival in the challenging environment. Effectors are powerful weapons ...
COLUMBUS, Ohio – Researchers have identified new roles for a protein long known to protect against severe flu infection – among them, raising the minimum number of viral particles needed to cause ...
Researchers have identified new roles for a protein long known to protect against severe flu infection—among them, raising the minimum number of viral particles needed to cause sickness. The protein ...
MUMBAI, India & HYDERABAD, India--(BUSINESS WIRE)--PopVax, an Indian full-stack biotechnology company developing novel mRNA vaccines and therapeutics using machine learning-enabled computational ...
Acurx (ACXP) Pharmaceuticals announced updates on Phase 3 Readiness for Ibezapolstat in C. difficile Infection based on recent FDA and EMA communications. Acurx’s Executive Chairman, Bob DeLuccia, ...
Lyon, France – July 28, 2023 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that The Lancet ...
Curevo is developing amezosvatein, a next-generation shingles vaccine currently in phase 2 testing. In head-to-head studies, the vaccine reportedly matched the immune response of the GSK Shingrix ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results